|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
25,420,000 |
Market
Cap: |
78.55(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$3.09 - $3.09 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile DermTech is a molecular diagnostic company developing and marketing non-invasive genomics tests to aid in the diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Co.'s focus is skin cancer. Co. provides the DermTech Melanoma Test for the early detection of melanoma and is developing a product for non-melanoma skin cancer. Co. is also working on products to assess precancerous genomic changes associated with sun UV exposure to the skin. Co. has additional skin cancer product offerings, including for non-melanoma skin cancers (basal cell and squamous cell cancers), under development.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
778 |
38,999 |
232,888 |
Total Sell Value |
$0 |
$1,128 |
$69,467 |
$590,685 |
Total People Sold |
0 |
2 |
4 |
6 |
Total Sell Transactions |
0 |
2 |
14 |
44 |
End Date |
2024-03-10 |
2023-12-08 |
2023-06-09 |
2022-06-09 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Salkind Gene |
Director |
|
2020-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
179,154 |
|
- |
|
Rosenman Herm |
Director |
|
2020-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
35,224 |
|
- |
|
Pancoast Scott R |
Director |
|
2020-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
25,894 |
|
- |
|
Collins Cynthia |
Director |
|
2020-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
25,483 |
|
- |
|
Dobak John |
Chief Executive Officer |
|
2020-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
26,901 |
466,181 |
|
- |
|
Wood Todd Michael |
Chief Commercial Officer |
|
2020-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
14,647 |
151,020 |
|
- |
|
Sun Kevin M |
Chief Financial Officer |
|
2020-01-17 |
4 |
A |
$0.00 |
$0 |
D/D |
132,032 |
132,032 |
|
- |
|
Posard Matthew L. |
Director |
|
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,994 |
29,263 |
|
- |
|
Yao Zuxu |
Chief Scientific Officer |
|
2019-12-31 |
4 |
D |
$12.40 |
$153,574 |
D/D |
(12,385) |
71,047 |
|
- |
|
Yao Zuxu |
Chief Scientific Officer |
|
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
39,934 |
83,432 |
|
- |
|
Jacobs Gary E. |
Director |
|
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,432 |
509,211 |
|
- |
|
Pancoast Scott R |
Director |
|
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,512 |
19,894 |
|
- |
|
Jansen Burkhard |
Chief Medical Officer |
|
2019-12-31 |
4 |
D |
$12.40 |
$182,813 |
D/D |
(14,743) |
71,165 |
|
- |
|
Jansen Burkhard |
Chief Medical Officer |
|
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
47,541 |
85,908 |
|
- |
|
Salkind Gene |
Director |
|
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,593 |
173,154 |
|
- |
|
Collins Cynthia |
Director |
|
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,755 |
19,483 |
|
- |
|
Dobak John |
Chief Executive Officer |
|
2019-12-31 |
4 |
D |
$12.40 |
$738,519 |
D/D |
(59,558) |
439,280 |
|
- |
|
Dobak John |
Chief Executive Officer |
|
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
155,720 |
498,838 |
|
- |
|
Rosenman Herm |
Director |
|
2019-12-31 |
4 |
OE |
$0.00 |
$0 |
D/D |
17,703 |
29,224 |
|
- |
|
119 Records found
|
|
Page 5 of 5 |
|
|